BuyDomino Search Change Region Menu

Bart Vansteenkiste

Global Key Account Manager – Life Sciences

avatarAlt

Bart Vansteenkiste is a global expert in pharmaceutical serialisation and aggregation with over 25 years of experience at Domino. He joined Domino's central-based Life Sciences sector team in 2011 to focus on EU FMD legislation, soon expanding to a global remit in 2016. As Domino's Global Key Account Manager for Life Sciences, he collaborates closely with the leading multinational pharmaceutical corporations (MNCs) and Original Equipment Manufacturers (OEMs) in the sector. Bart also frequently presents on behalf of Domino at international conferences and is fluent in English, Spanish, French, and Dutch.

Articles from Bart Vansteenkiste

Covid-19: Key considerations when printing onto masks

Understanding how to add the necessary codes to masks is crucial for manufacturers – both for the efficiency of their business and the safety of their customers. There are health risks associated with incorrect coding practices. And different types of mask have different coding requirements. Let’s outline the key considerations.

BLOG

Become compliant with the Russian cryptocode legislation

Time is running out for companies to prepare for the new Russian coding legislation. Here is everything you need to know about becoming compliant.

BLOG

Pharma Serialisation: 5 Key Benefits

Implementing item-level serialisation is a major challenge for pharmaceutical businesses. But it promises significant benefits – both for individual businesses and the industry as a whole. And the earlier you make the transition, the better.

BLOG

EU Falsified Medicines Directive - Q&A

Bart Vansteenkiste, European Life Sciences Sector Manager answers some general Question about European Union Falsified Medicines Directive.

BLOG

The future of pharmaceutical data management

Pharmaceutical businesses are staring at a sea of change in the way medication is tracked. Legislation has been passed to implement item-level serialisation. Essentially each individual bottle or packet of medication must be able to be tracked from production line to patient. That poses a huge data management challenge and impacts almost every business function in the pharmaceutical industry. Here’s what you need to know.

BLOG

Other Pharma Emerging Legislation

The pharmaceutical sector is facing its greatest challenge to date; how to reduce the number of counterfeit and falsified medicines entering the legitimate supply chain.

BLOG

China CFDA eCode

The China Food and Drug Administration (CFDA) work to ensure the safety of food and healthcare products in the Chinese market. The drug regulation aims to protect patients from counterfeit pharmaceuticals and counterfeit traditional Chinese medicines.

BLOG

EU Falsified Medicines Directive (FMD 2011/62/EU)

​Adopted in 2011 the EU Falsified Medicines Directive (FMD 2011/62/EU) aims to decrease incidents of falsified medicines reaching the open market within the European Economic area resulting in improved patient safety.

BLOG